Shanghai Healthcare Capital

Brattea is a medical device research and development company. Brattea focuses on the development and commercialization of renal denervation products with indications in hypertension, cancer pain and diabetes.

Geneos Therapeutics, Inc. is focused on producing and developing neoantigen-targeting cancer immunotherapies. Founded in 2016 and headquartered in Plymouth Meeting, Pennsylvania, the company utilizes its Geneos Platform to create personalized therapies that are tailored to the unique tumor mutations of each patient. This innovative approach involves identifying relevant neoantigen targets from individual tumors, allowing for the development of novel treatments aimed at providing targeted immunotherapies for various types of cancer. By offering these customized solutions, Geneos seeks to enhance the effectiveness of cancer treatment and improve outcomes for patients.

Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.

ReLive is a biotechnology company that develops orthopedic sports medicine and plastic and reconstructive surgery projects based on regenerative medicine and cell therapy science.

ArriVent Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative treatments for currently untreatable cancers. The company is committed to addressing unmet medical needs in oncology by leveraging its team's extensive drug development experience. ArriVent aims to maximize the potential of its lead candidate, furmonertinib, while advancing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. With an initial emphasis on solid tumors, ArriVent seeks to bring differentiated medicines from development through to commercialization, ultimately improving patient outcomes in cancer treatment.

Biomica is a biopharmaceutical company that develops microbiome-based therapeutics to treat immune-mediated and infectious diseases, with specific focus on Immuno-Oncology and GI-related disorders.

Ranok Therapeutics is a biotechnology company focused on developing targeted protein degradation technology to discover and create new therapeutics. This innovative approach engages various biological processes and demonstrates superiority over existing targeted protein degradation methods. The company's pipeline includes both well-established and novel drug targets associated with cancer and other diseases that present significant unmet medical needs. Ranok is committed to advancing the next generation of cancer therapies that prioritize safety and effectiveness for patients facing serious health challenges.

Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.

Immvira, founded in Shenzhen, China, in May 2015 by a group of prominent professors from various universities, is focused on developing biopharmaceutical technology in the field of immunotherapy. The company specializes in creating oncolytic viruses and vector-type approaches aimed at treating cancer. Its primary product is a genetically engineered Oncolytic Herpes Simplex Virus, which is designed to target metastatic tumors or tumors that are difficult to access by direct injection. By leveraging this innovative technology, Immvira aims to provide more effective treatment solutions for patients suffering from cancer.

VeriSilicon Holdings Co., Ltd. is an integrated circuit design foundry that specializes in providing custom silicon solutions and system-on-chip (SoC) turnkey services for a diverse array of electronic devices and systems. Its offerings cater to sectors such as smartphones, media tablets, HDTVs, set-top boxes, and data centers. The company leverages its extensive portfolio of in-house semiconductor intellectual property (IP), which includes various processor IPs like GPU, NPU, VPU, DSP, and ISP, as well as over 1,400 analog, mixed-signal, and RF IPs. VeriSilicon's technology solutions also encompass licensable digital signal processing cores and video IPs, enabling high-definition video, audio, and IoT connectivity. The firm supports a wide range of process technologies, including advanced nodes like 28nm and FD-SOI, positioning itself as a comprehensive provider of semiconductor solutions.